ZIOP Key Statistics, Chart & Performance
The current stock price of ZIOP is 0.8657 null. In the past month the price decreased by -22.01%. In the past year, price decreased by -76.67%.
ZIOP Latest News, Press Relases and Analysis
ZIOP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About ZIOP
Company Profile
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Company Info
ZIOPHARM ONCOLOGY INC
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston MASSACHUSETTS 02129 US
CEO: Heidi Hagen
Employees: 103
Phone: 16172591970.0
ZIOPHARM ONCOLOGY INC / ZIOP FAQ
What does ZIOP do?
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
What is the current price of ZIOP stock?
The current stock price of ZIOP is 0.8657 null. The price decreased by -0.88% in the last trading session.
Does ZIOPHARM ONCOLOGY INC pay dividends?
ZIOP does not pay a dividend.
How is the ChartMill rating for ZIOPHARM ONCOLOGY INC?
ZIOP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is ZIOPHARM ONCOLOGY INC worth?
ZIOPHARM ONCOLOGY INC (ZIOP) has a market capitalization of 187.12M null. This makes ZIOP a Micro Cap stock.
ZIOP Technical Analysis
ZIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZIOP. Both the profitability and financial health of ZIOP have multiple concerns.
ZIOP Financial Highlights
Over the last trailing twelve months ZIOP reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -22543.47% | ||
| ROA | -78.87% | ||
| ROE | N/A | ||
| Debt/Equity | 0.18 |
ZIOP Forecast & Estimates
13 analysts have analysed ZIOP and the average price target is 4 null. This implies a price increase of 361.48% is expected in the next year compared to the current price of 0.8657.